192 related articles for article (PubMed ID: 20166183)
1. Increased proportion of the CD56(bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-alpha and ribavirin therapy.
Lee S; Watson MW; Flexman JP; Cheng W; Hammond T; Price P
J Med Virol; 2010 Apr; 82(4):568-74. PubMed ID: 20166183
[TBL] [Abstract][Full Text] [Related]
2. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment.
Gonzalez VD; Falconer K; Björkström NK; Blom KG; Weiland O; Ljunggren HG; Alaeus A; Sandberg JK
J Immunol; 2009 Nov; 183(10):6612-8. PubMed ID: 19846870
[TBL] [Abstract][Full Text] [Related]
3. Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure.
Golden-Mason L; Madrigal-Estebas L; McGrath E; Conroy MJ; Ryan EJ; Hegarty JE; O'Farrelly C; Doherty DG
Gut; 2008 Aug; 57(8):1121-8. PubMed ID: 18372499
[TBL] [Abstract][Full Text] [Related]
4. CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection.
Lin AW; Gonzalez SA; Cunningham-Rundles S; Dorante G; Marshall S; Tignor A; Ha C; Jacobson IM; Talal AH
Clin Exp Immunol; 2004 Aug; 137(2):408-16. PubMed ID: 15270860
[TBL] [Abstract][Full Text] [Related]
5. Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin.
Gonzalez VD; Falconer K; Michaëlsson J; Moll M; Reichard O; Alaeus A; Sandberg JK
Clin Immunol; 2008 Jul; 128(1):46-56. PubMed ID: 18495540
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cell activity and function in chronic HCV-infected patients during peg interferon and ribavirin: early effects of active substance use.
Hotho DM; Kreefft K; Groothuismink ZM; Janssen HL; de Knegt RJ; Boonstra A
Antiviral Res; 2013 Mar; 97(3):347-55. PubMed ID: 23291200
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of CD81 expression on lymphocyte subsets during interferon-alpha-based antiviral treatment of patients with chronic hepatitis C.
Kronenberger B; Herrmann E; Hofmann WP; Wedemeyer H; Sester M; Mihm U; Ghaliai T; Zeuzem S; Sarrazin C
J Leukoc Biol; 2006 Aug; 80(2):298-308. PubMed ID: 16735696
[TBL] [Abstract][Full Text] [Related]
8. Human CD56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guérin.
Batoni G; Esin S; Favilli F; Pardini M; Bottai D; Maisetta G; Florio W; Campa M
Scand J Immunol; 2005 Dec; 62(6):498-506. PubMed ID: 16316416
[TBL] [Abstract][Full Text] [Related]
9. Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C.
Bonorino P; Ramzan M; Camous X; Dufeu-Duchesne T; Thélu MA; Sturm N; Dariz A; Guillermet C; Pernollet M; Zarski JP; Marche PN; Leroy V; Jouvin-Marche E
J Hepatol; 2009 Sep; 51(3):458-67. PubMed ID: 19596474
[TBL] [Abstract][Full Text] [Related]
10. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection.
Stegmann KA; Björkström NK; Veber H; Ciesek S; Riese P; Wiegand J; Hadem J; Suneetha PV; Jaroszewicz J; Wang C; Schlaphoff V; Fytili P; Cornberg M; Manns MP; Geffers R; Pietschmann T; Guzmán CA; Ljunggren HG; Wedemeyer H
Gastroenterology; 2010 May; 138(5):1885-97. PubMed ID: 20334827
[TBL] [Abstract][Full Text] [Related]
11. Increased frequency of CD56Bright NK-cells, CD3-CD16+CD56- NK-cells and activated CD4+T-cells or B-cells in parallel with CD4+CDC25High T-cells control potentially viremia in blood donors with HCV.
Zarife MA; Reis EA; Carmo TM; Lopes GB; Brandão EC; Silva HR; Santana N; Martins-Filho OA; Reis MG
J Med Virol; 2009 Jan; 81(1):49-59. PubMed ID: 19031471
[TBL] [Abstract][Full Text] [Related]
12. Altered distribution of natural killer cell subsets identified by CD56, CD27 and CD70 in primary and chronic human immunodeficiency virus-1 infection.
Titanji K; Sammicheli S; De Milito A; Mantegani P; Fortis C; Berg L; Kärre K; Travi G; Tassandin C; Lopalco L; Rethi B; Tambussi G; Chiodi F
Immunology; 2008 Feb; 123(2):164-70. PubMed ID: 17627773
[TBL] [Abstract][Full Text] [Related]
13. [Alteration of CD100 expression on natural killer cells in chronic patients with hepatitis C virus before and after initiation of antiviral treatment].
He Y; Li B; Zhou Y; Zhang Y; Guo Y; Ji G; Fan C; Jia Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Aug; 30(8):856-60. PubMed ID: 25108441
[TBL] [Abstract][Full Text] [Related]
14. The correlation between the percent of CD3- CD56+ cells and NK precursor function.
Gharehbaghian A; Donaldson C; Newman J; Bannister G; Bradley BA
Iran J Allergy Asthma Immunol; 2006 Dec; 5(4):167-75. PubMed ID: 17237569
[TBL] [Abstract][Full Text] [Related]
15. Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity.
Hu PF; Hultin LE; Hultin P; Hausner MA; Hirji K; Jewett A; Bonavida B; Detels R; Giorgi JV
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Nov; 10(3):331-40. PubMed ID: 7552495
[TBL] [Abstract][Full Text] [Related]
16. Chronic hepatitis C in the advanced adult and elderly subjects.
Gattoni A; Parlato A; Vangieri B; Bresciani M; Petraccaro M
Minerva Gastroenterol Dietol; 2009 Jun; 55(2):145-57. PubMed ID: 19305374
[TBL] [Abstract][Full Text] [Related]
17. NK cells prevalence, subsets and function in viral hepatitis C.
Zeromski J; Mozer-Lisewska I; Kaczmarek M; Kowala-Piaskowska A; Sikora J
Arch Immunol Ther Exp (Warsz); 2011 Dec; 59(6):449-55. PubMed ID: 21972016
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment intrahepatic CD8+ cell count correlates with virological response to antiviral therapy in chronic hepatitis C virus infection.
Vrolijk JM; Kwekkeboom J; Janssen HL; Hansen BE; Zondervan PE; Osterhaus AD; Schalm SW; Haagmans BL
J Infect Dis; 2003 Nov; 188(10):1528-32. PubMed ID: 14624378
[TBL] [Abstract][Full Text] [Related]
19. Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing.
Morishima C; Paschal DM; Wang CC; Yoshihara CS; Wood BL; Yeo AE; Emerson SS; Shuhart MC; Gretch DR
Hepatology; 2006 Mar; 43(3):573-80. PubMed ID: 16496327
[TBL] [Abstract][Full Text] [Related]
20. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
